natgillin/translations-raw huggingface dataset:
Undesirable effects include mild to moderate yellow/ orange discoloration of the skin, mucous membranes, sclera, dark faeces and discoloured or turbid urine due to metabolism and/ or excretion of haemoglobin.
Neželeni učinki vključujejo blago do zmerno rumeno/ oranžno obarvanje kože, sluznic, beločnice, temno blato in obarvan ali moten urin zaradi presnove in/ ali izločanja hemoglobina.
A commonly observed undesirable effect was circulatory overload with associated clinical signs such as tachypnea, dyspnea, harsh lung sounds and pulmonary edaema.
Pogosto opaženi stranski učinek je bila preobremenitev krvnega obtoka z odgovarjajočimi kliničnimi znaki, kot so tahipneja, dispneja, rezki glasovi v pljučih in pljučni edem.
The recommended dosage of Oxyglobin is 30 ml/ kg of body weight administered intravenously at a rate up to 10 ml/ kg/ hr.
Priporočeni odmerek Oxyglobina je 30 ml/ kg telesne mase, dan intravensko s hitrostjo do 10 ml/ kg/ uro.
In certain clinical situations, a dosage of 15-30 ml/ kg may be appropriate.
Pri nekaterih kliničnih stanjih je primeren odmerek 15- 30 ml/ kg.
3 Table A:
3 Preglednica A:
Pharmacokinetic Parameters at Multiple Dose Levels after a Single Infusion of Oxyglobin
Farmakokinetični parametri pri ponovljenih odmerkih po enkratni infuziji Oxyglobina
(ml/ kg)
Odmerek (ml/ kg)
concentration* (g/ dl)
Koncentracija v plazmi takoj po infuziji * (g/ dl)
1 g/ dl
Trajanje( ure): koncentracije Oxyglobina nad 1 g/ dl
(days)***
Izčistek iz plazme (dnevi) ***
range based on mean ± SD range based on estimated mean value with bounds of a 95% prediction interval range based on 5 terminal half-lives
** razpon, zasnovan na ocenjeni srednji vrednosti, z mejami 95% napovedanega intervala *** razpon na osnovi 5 končnih razpolovnih časov.
As with any intravenous fluid administration, Oxyglobin should be warmed to 37° C prior to administration.
Tako kot vsako intravensko tekočino, je treba Oxyglobin pred uporabo segreti na 37° C.
Do not microwave.
Ne segrevajte ga v mikrovalovni pečici.
Use of Oxyglobin does not require typing or cross – matching of the recipient ’ s blood.
Pri uporabi Oxyglobina ni treba določati krvne skupine ali navzkrižno preverjati prejemnika infuzije.
Overdosage or an excessive rate of administration (i. e., > 10 ml/ kg/ hr) could result in immediate cardiopulmonary effects, in which case infusion of Oxyglobin should be discontinued immediately until signs abate.
Preveliki odmerki ali prehitro dajanje (tj. > 10 ml/ kg/ uro) lahko povzročijo takojšnje kardiopulmonarne učinke.
Treatment of circulatory overload may be necessary.
V tem primeru je treba takoj ustaviti infuzijo Oxyglobina, dokler se znaki ne ublažijo.
Blood substitutes, ATCvet code:
Nadomestki za kri, oznaka ATC vet:
The plasma half-life is 30- 40 hours.
Njegova razpolovna doba v plazmi je 30- 40 ur.
It is eliminated from the plasma in 5-7 days.
Iz plazme se izloči po 5- 7 dneh.
Haemoglobin dissociates in plasma and is progressively incorporated in the protein pool of the organism.
Hemoglobin se razkroji v plazmi in se postopoma vgrajuje v beljakovinske zaloge v organizmu.
A small amount of unstabilised tetrameric haemoglobin (< 5%) may be excreted through the kidneys, resulting in transient haemoglobinuria for < 4 hours.
Majhna količina nestabiliziranega tetramernega hemoglobina (< 5%) se lahko izloči skozi ledvice, kar povzroči prehodno hemoglobinurijo, ki traja manj kot 4 ure.
Water for injection, NaCl KCl CaC12 2H2O NaOH Sodium lactate N-acetyl-l cysteine
Modificirana raztopina Ringerjevega laktata, ki vsebuje običajne sestavine: vodo za injekcije, NaCl, KCl, CaC12 2H2O, NaOH, natrijev laktat, N- acetil- l cistein.
3 years Shelf-life after first opening the immediate packaging:
6. 3 Rok uporabnosti
A box with two (2) polyolefin infusion bags (60 ml), each within an overwrap.
Škatla z dvema( 2) poliolefinskima infuzijskima vrečkama (60 ml), vsaka v zunanjem ovoju.
A box with two (2) polyolefin infusion bags (125 ml), each within an overwrap.
Škatla z dvema( 2) poliolefinskima infuzijskima vrečkama (125 ml), vsaka v zunanjem ovoju.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /
Name and address of the manufacturer of the biological active substance Biopure Corporation 39 Hurley Street Cambridge MA 02141 USA
Biopure Corporation 39 Hurley Street Cambridge MA 02141 USA
Name and address of the manufacturer responsible for batch release Dales Pharmaceutical Ltd.
Ime in naslov izdelovalca zdravila, odgovornega za sproščanje serije Dales Pharmaceutical Ltd.
Oxyglobin 130 mg/ ml Solution for infusion for dogs.
Oxyglobin 130 mg/ ml, raztopina za infundiranje za pse
Hemoglobin glutamer-200 (bovine) – 130 mg/ ml
Hemoglobin glutamer- 200 (goveji) – 130 mg/ ml
Two single dose bags (60 ml) for intravenous infusion each within an overwrap< outer box > Overwrap containing a 60 ml infusion bag < overwrap> 60 ml infusion bag < infusion bag >
(Infuzijska vrečka).
Two single dose bags (125 ml) for intravenous infusion each within an overwrap< outer box > Overwrap containing a 125 ml infusion bag < overwrap> 125 ml infusion bag < infusion bag >
(Infuzijska vrečka).
Oxyglobin is intended for single intravenous administration by infusion.
Pred uporabo preberite navodilo za uporabo.
Do not overheat > 37° C.
Ne segrevajte pri več kot 37° C.
< EXP {month/year} >
< EXP {mesec/ leto} >
Oxyglobin 130 mg/ ml Solution for infusion for dogs
13 NAVODILO ZA UPORABO Oxyglobin 130 mg/ ml, raztopina za infundiranje za pse
Oxyglobin 130 mg/ ml Solution for infusion for dogs
Oxyglobin 130 mg/ ml, raztopina za infundiranje za pse
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
NAVEDBA ZDRAVILNE( IH) UČINKOVIN( E) IN DRUGEIH SESTAVIN
During the clinical safety and efficacy study, adverse events were seen which may have been related to Oxyglobin and/ or the underlying disease causing anaemia.
V raziskavi o klinični varnosti in učinkovitosti zdravila so opazili neželene pojave, ki so bili morda povezani z Oxyglobinom in/ ali osnovno boleznijo, ki povzroča anemijo.
Side effects which were observed included mild to moderate discolouration of the mucous membranes, sclera, and urine due to metabolism and/ or excretion of haemoglobin.
Med opaženimi neželenimi učinki so bili blago do zmerno obarvanje sluznic, beločnice in urina zaradi presnove in/ ali izločanja hemoglobina.
Effects commonly seen were vomiting, loss of appetite, fever, and circulatory overload with associated clinical signs such as tachypnea, dyspnea, harsh lung sounds, and pulmonary edaema; circulatory overload was controlled by slowing the rate of administration.
Preveliko obremenitev krvnega obtoka so nadzorovali z upočasnjenim dajanjem zdravila.
The optimum dosage is based upon the degree and chronicity of the anemia and the desired duration of the effect.
Optimalni odmerki so odvisni od stopnje in kroničnosti anemije ter od želenega trajanja učinka.
(See Table A Pharmacokinetic Parameters)
Farmakokinetični parametri.)
Table A:
(Glej Preglednico A
Duration hours):
Preglednica A:
1 g/ dL
Trajanje (ure): koncentracije Oxyglobina nad 1 g/ dl
2.0 – 2.5 3.4 – 4.3 3.6 – 4.8
2, 0 – 2, 5 3, 4 – 4, 3
range based on mean ± SD
* razpon na osnovi srednje vrednosti
** range based on estimated mean value with bounds of a 95% prediction interval *** range based on 5 terminal half-lives
** razpon, zasnovan na ocenjeni srednji vrednosti, z mejami 95% napovedanega intervala *** razpon na osnovi 5 končnih razpolovnih časov.
As with any intravenous fluid administration, Oxyglobin should be warmed to 37° C prior to administration.
Tako kot pred uporabo vsake intravenske tekočine, je treba Oxyglobin segreti na 37° C.
Do not store above 30°C.
Ne shranjujte zamrzovalniku.
Due to the plasma expanding properties of Oxyglobin, the possibility of circulatory overload should be considered especially when administering adjunctive intravenous fluids, particularly colloidal solutions. circulatory overload should be carefully monitored or central venous pressure (CVP) CVP increases
Znake preobremenjenosti krvnega obtoka je treba skrbno spremljati ali meriti centralni venski tlak (CVP).
to a clinically unacceptable level and/ or if signs of circulatory overload are observed, the infusion of Oxyglobin should be temporarily discontinued and re-instituted at a slower rate when signs abate and/ or CVP decreases.
Če se CVP zveča na klinično nesprejemljivo vrednost in/ ali če so opaženi znaki preobremenjenosti krvnega obtoka, je treba začasno prenehati dajati Oxyglobin in ga ponovno začeti dajati počasneje, ko se znaki ublažijo in/ ali ko se vrednost CVP zmanjša.
EMEA/ V/ C/ 054 EMEA/ CVMP/ 417488/ 2006
EMEA/ V/ C/ 054 EMEA/ CVMP/ 468773/ 2006
It works by blocking the bacteria’ s ribosomes; this is the part of the cell where proteins are produced.
Deluje tako, da blokira delovanje bakterijskih ribosomov, ki v celicah tvorijo beljakovine.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Pirsue shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 47 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2006 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo Pirsue izkazalo med raziskavami?
Pirlimycin hydrochloride can cause severe eye and skin irritation.
Z zdravilom Pirsue je zato treba ravnati previdno, da preprečimo stik z raztopino.
Care should, therefore, be taken by the user of the product to avoid contact with the solution.
Kožo, ki je prišla v stik z zdravilom Pirsue, je treba umiti.
Information on the prescription status of this product may be found on the label/ outer package.
Informacije o predpisovanju tega zdravila lahko najdete na notranji/ zunanji ovojnini.
This summary was last updated in November 2006.
Ta povzetek je bil nazadnje posodobljen 11- 2006.
Page 2/ 2 ©EMEA 2006
stran 2/ 2 ©EMEA 2006
MA Numbers
EU številka
EU/ 2/ 00/ 027/ 001 PIRSUE
EU/ 2/ 00/ 027/ 001
Intramammary Solution
Intramamarna raztopina
Intramammary Use
intramamarna aplikacija
Pre-filled syringe (PE)
intramamarni injektor (PE)
8 pre-filled syringes (in a cardboard box)
8 injektorjev (v kartonski škatli)
23 days Milk:
Mleko:
24 pre-filled syringes (in a cardboard box)
24 injektorjev (v kartonski škatli)
EU/ 2/ 00/ 027/ 003 PIRSUE
EU/ 2/ 00/ 027/ 003
120 pre-filled syringes (in a plastic bucket)
120 injektorjev (v plastičnem vedru)
PIRSUE 5 mg/ ml intramammary solution for cattle
PIRSUE 5 mg/ ml intramamarna raztopina za govedo
For a full list of excipients see Section 6.1
Celoten seznam pomožnih snovi, glej razdelek 6. 1.
For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.
Za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo grampozitivni koki, občutljivi na pirlimicin, vključno s stafilokoki kot so Staphylococcus aureus (penicilinaza pozitivni, penicilinaza negativni in koagulaza negativni stafilokoki), streptokoki, vključno Streptococcus agalctiae, Streptococcus dysgalactiae in Streptococcus uberis.
Treatment of infections due to Gram-negative bacteria such as E. coli.
Zdravljenje infekcij, ki jih povzročajo gramnegativne bakterija kot je E. coli.
6 Adverse reactions (frequency and seriousness)
Stranski učinki (pogostost in resnost)
Remove the white end cap by pulling straight up.
Vnos: s potegom odstranite bel pokrovček.
23 days.
23 dni.
5 days.
5 dni.
Antibacterial for intramammary use ATCvet code:
Antibiotiki za intramamarno uporabo Oznaka ATCvet:
They work by binding to the 50S ribosomal subunit, therefore hindering the aminoacyl-tRNA binding and inhibiting the peptidyltransferase reaction, which interferes with protein synthesis within the bacteria.
Delujejo tako, da preprečuje sintezo beljakovin s tem, da se veže na podenoto bakterijskega ribosoma (50S), s tem zavirajo vezavo aminoacilne- tRNK, kar pri občutljivih bakterijah povzroči moteno aktivnost peptidiltransferaze.
3 Gram-positive isolates with an MIC > 2 µg/ ml are to be considered resistant.
3 Grampozitivni izolati z MIC > 2 µg/ ml se štejejo kot rezistentni.
Enteric bacteria such as E. coli are intrinsically resistant to pirlimycin.
Coli so rezistentne na pirlimicin.
Pirlimycin has a basic pKa (8.5).
Pirlimicin ima bazično pKa (8, 5).
After intramammary infusion, mean parent concentrations in milk were 10.3 µg/ ml at 12 hours and 0.77 µg/ ml at 24 hours.
Po intramamarni infuziji je bila koncentracija v mleku 10, 3 µg/ ml v 12 urah in 0, 77 µg/ ml v 24 urah.
Of the dose infused, 10-13% is excreted in the urine, and 24-30% via the faeces; the remainder is excreted in the milk.
Po vnosu enkratnega odmerka se 10- 13% zdravila izloči z urinom in 24- 30% z iztrebki, preostanek pa se izloči z mlekom.
Anhydrous citric acid Sodium citrate Water for injection
Brezvodna citronska kislina Natrijev citrat Voda za injekcije
Do not store above 25° C.
Shranjujte pri temperaturi do 25°C.
Sterile aqueous solution in 10 ml polyethylene intramammary syringes, packaged as 8 x 10 ml, 24 x 10 ml in an outer cardboard box.
8x10 ml ali 24x10 ml injektorjev.
Any unused veterinary medical product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
Vsako neuporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ UK
Ramsgate Road Sandwich Kent CT13 9NJ Velika Britanija
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /.
THE MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
IMETNIK( I) DOVOLJENJ( A) ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Rijksweg 12 2870 Puurs Belgium
Rijksweg 12 2870 Puurs Belgija
In accordance with Council Regulation (EEC) No 2377/ 90, as amended and in accordance with Article 34.4b of Regulation (EEC) No 726/ 2004 of 31 March 2004.
726/ 2004 z dne 31. marca 2004.
Pirlimycin is included in Annex I of Council Regulation (EEC) No 2377/ 90 in accordance with the following table:
2377/ 90 v skladu z naslednjo tabelo:
MRLs
Najvišje dovoljene
provisions
količine zaostankov (MRL)
Pirlimycin1 Pirlimycin
določbe
Bovine
Pirlimicin1
Muscle
govedo
Fat Liver Kidney Milk
meso maščoba jetra ledvica mleko
Anhydrous citric acid (E 330) and Sodium citrate (E 331) are approved as additives in foodstuffs for human consumption and therefore covered by Annex II of Council Regulation (EEC) No.
Brezvodna citronska kislina (E330) in natrijev citrat (E331) sta odobrena kot aditiva v živilih za humano porabo in kot taka vključena v Dodatek II Uredbe Sveta (EGS) št.
2377/ 90 for substances with an E- number2 (with the exception of preservatives listed in part C of Annex III to Council Directive 95/ 2/ EC3.).
2377/ 90 za substance z E - številko2 (z izjemami konzervansov, navedenih v Dodatku III Uredbe Sveta 95/ 2/ EGS3.).
1 OJ No L269 of 20.10.2000, p.
1 UL L269, 20. 10. 2000, str.
21 2 OJ No L272 of 25.10.1996, p.
21 2 UL L272, 25. 10. 1996, str.
2 3 OJ Nº L 61 of 18.3.1995, p.
2 3 UL L 61, 18. 3. 1995, str.
9 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
9 PODATKI NA ZUNANJI OVOJNINI, PODATKI NA STIČNI OZ.
8 x 10 ml syringes in an outer carton box 24 x 10 ml syringes in an outer carton box, including 3 package inserts 120 x 10 ml syringes in a plastic bucket, including 15 package inserts
8×10 ml injekorji 24×10 ml injektorji, dodana 3 navodila za uporabo 120×10 ml injektorji, dodanih 15 navodil za uporabo
8 x 10 ml intramammary syringes 24 x 10 ml intramammary syringes 120 x 10 ml intramammary syringes
120 x 10 ml intramamarnih injektorjev.
Remove the white end cap by pulling straight up.
10 Vnos: s potegom odstranite bel pokrovček.
Withdrawal period:
Meso in organi:
Keep the syringes in the outer carton.
Shranjujte injektorje v originalni ovojnini.
Any unused veterinary medical product or waste materials derived from such medicinal products should be disposed of in accordance with the local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
To be supplied only on veterinary prescription.
Zdravilo se izda le na veterinarski recept.
14 PACKAGE LEAFLET PIRSUE 5 mg/ ml intramammary solution for cattle
14 NAVODILO ZA UPORABO PIRSUE 5 mg/ ml intramamarna raztopina za govedo
Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ UK
Ramsgate Road Sandwich Kent CT13 9NJ Velika Britanija.
Rijksweg 12 B-2870 Puurs Belgium
Pfizer Manufacturing Belgium NV Rijksweg 12 B- 2870 Puurs Belgija
For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.
Za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije, ki ga povzročajo grampozitivni koki, občutljivi na pirlimicin, vključno s stafilokoki kot so Staphylococcus aureus (penicilinaza pozitivni, penicilinaza negativni in koagulaza negativni stafilokoki), streptokoki, vključno Streptococcus agalctiae, Streptococcus dysgalactiae in Streptococcus uberis.
Treatment of infections due to Gram-negative bacteria such as E. coli.
Zdravljenje infekcij, ki jih povzroča gramnegativne bakterija kot je E. coli.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Če opazite kakršne koli resne stranske učinke, ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite svojega veterinarja.
Keep out of the reach and sight of children Do not store above 25° C.
Shranjujte pri temperaturi do 25°C.
Do not use after the expiry date stated on the label and the container.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki oziroma zunanji ovojnini.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY 16 Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neuporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
Route of administration
Ciljna Pot uporabe živalska vrsta
Package size
Ovojnina Vsebina
≥ 5.9 log2 TN titre protein dO ≥ 4.2 log2 Agglutination titre Inactivated Bordetella bronchiseptica cells
≥ 5, 9 log2 toksin nevtralizirajočega titra proteina dO ≥ 4, 2 log2 aglutinacijskega titra inaktiviranih celic bakterije Bordetella bronchiseptica
Pigs (sows, gilts)
prašiči intramuskularno (svinje, mladice)
1 vial per cardboard box
1 viala v zloženki
≥ 5.9 log2 TN titre protein dO ≥ 4.2 log2 Agglutination titre Inactivated Bordetella bronchiseptica cells
≥ 5, 9 log2 toksin nevtralizirajočega titra proteina dO
Pigs (sows, gilts)
prašiči intramuskularno (svinje,
Vial (polyethylene terephthalate [PET])
viala (polietilen
What is Porcilis AR-T DF?
Kaj je zdravilo Porcilis AR- T DF?
Porcilis AR-T DF is a vaccine for use in pigs.
Zdravilo Porcilis AR- T DF je cepivo, ki se uporablja pri prašičih.
It is a vial containing a suspension for injection.
Gre za vialo, ki vsebuje suspenzijo za injiciranje.
Porcilis AR-T DF contains a non-toxic recombinant derivative (see ‘ How does Porcilis AR-T DF work? ’) of the Pasteurella multocida toxin and inactivated Bordetella bronchiseptica cells.
Zdravilo Porcilis AR- T DF vsebuje netoksični rekombinantni derivat (glejte » Kako zdravilo Porcilis AR- T DF deluje? «) toksina Pasteurella multocida in inaktiviranih celic Bordetella bronchiseptica.
What is Porcilis AR-T DF used for?
Za kaj se zdravilo Porcilis AR- T DF uporablja?
Porcilis AR-T DF is used to reduce the clinical signs of progressive atrophic rhinitis (a disease where the nose tissues become infected and die) in piglets.
Zdravilo Porcilis AR- T DF se uporablja za zmanjšanje kliničnih znakov progresivnega atrofičnega rinitisa (bolezni, pri kateri pride do okužbe nosnih tkiv, ki nato odmre).
Their piglets then become immunised when they drink the colostrum (first milk).
Njihovi pujski postanejo s pitjem kolostruma (prvega mleka) imuni.
Porcilis AR-T DF is given as a dose of 2 ml by intramuscular (into a muscle) injection to female pigs of 18 weeks of age and older.
Zdravilo Porcilis AR- T DF se daje svinjam (samicam), starim 18 tednov in starejšim, v odmerku 2 ml z intramuskularno (v mišico) injekcijo.
The first injection should be given 6 weeks before the expected date of farrowing (giving birth to the piglets).
Prvo injekcijo je treba dati 6 tednov pred pričakovano prasitvijo (rojevanjem pujskov).
The first dose is followed by a second injection 4 weeks later.
Prvemu odmerku sledi drugi 4 tedne kasneje.
To maintain the immunity, a single injection of one dose should be carried out 2 – 4 weeks before each subsequent farrowing.
Za vzdrževanje imunosti je potrebna ena injekcija (en odmerek) 2 do 4 tedne pred vsako naslednjo prasitvijo.
How does Porcilis AR-T DF work?
Kako zdravilo Porcilis AR- T DF deluje?
Porcilis AR-T DF contains a non-toxic recombinant derivative (see later) of the Pasteurella multocida toxin and also inactivated Bordetella bronchiseptica bacterial cells.
Zdravilo Porcilis AR- T DF vsebuje netoksični rekombinantni derivat (glejte spodaj) toksina bakterije Pasteurella multocida in tudi inaktivirane celice bakterije Bordetella bronchiseptica.
When the sow is injected, this small exposure helps the pig’ s immune system to recognise and attack the bacteria.
Ko svinja prejme injekcijo, ta majhna izpostavitev pripomore, da njen imunski sistem prepozna in napade bakterijo.
When exposed to any of these bacteria later in life, the pig will either not become infected or have a much less serious infection.
Če bo kasneje v življenju prašič izpostavljen tem sevom, se ne bo okužil oziroma bo imel bistveno manj resno okužbo.
This immunity is passed onto the sow’ s piglets through her colostrum.
Imunost se preko kolostruma prenaša s svinje na pujske.
An active ingredient of Porcilis AR-T DF, Pasteurella multocida toxin, is produced by a method known as ‘ recombinant technology’.
Zdravilna učinkovina zdravila Porcilis AR- T DF, toksin Pasteurella multocida, se proizvaja po metodi, imenovani » rekombinantna tehnologija «.
The Pasteurella multocida toxin is made by a bacterium cell that has received a gene (DNA), which makes it able to produce Pasteurella multocida toxoid, a genetically modified form of toxin which has adequate immunogenic activity and which is free from the toxic properties.
Toksin Pasteurella multocida proizvaja celica bakterije, ki je prejela gen (DNK), ki ji omogoča tvorjenje toksoida Pasteurella multocida, t. j. genetsko modificirane oblike toksina, ki ima zadostno imunogenost, vendar pa nima toksičnih lastnosti.